A5033438994- Cardiac Valve Diseases and Treatments
- Coronary Interventions and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiovascular Function and Risk Factors
- Vascular Procedures and Complications
- Atrial Fibrillation Management and Outcomes
- Aortic Disease and Treatment Approaches
- Cerebrovascular and Carotid Artery Diseases
- Cardiovascular Disease and Adiposity
- Cardiac pacing and defibrillation studies
- Cardiac Arrhythmias and Treatments
- Peripheral Artery Disease Management
- Inflammatory Biomarkers in Disease Prognosis
- Reconstructive Surgery and Microvascular Techniques
- Cardiac and Coronary Surgery Techniques
- Venous Thromboembolism Diagnosis and Management
- Cardiac Structural Anomalies and Repair
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pulmonary Hypertension Research and Treatments
- Acute Myocardial Infarction Research
- Cardiac, Anesthesia and Surgical Outcomes
- Hemodynamic Monitoring and Therapy
- Kawasaki Disease and Coronary Complications
Medical University of South Carolina
2019-2025
New York University
2011-2019
New York Hospital Queens
2019
Mount Sinai Beth Israel
2019
NYU Langone Health
2018
Williams & Associates
2018
Columbia University Irving Medical Center
2017
VA NY Harbor Healthcare System
2011-2014
Istituto Nazionale di Fisica Nucleare
2014
University of Nebraska at Omaha
2012-2013
Background— Drug-eluting stents (DES) have been in clinical use for nearly a decade; however, the relative short- and long-term efficacy safety of DES compared with bare-metal (BMS) among types are less well defined. Methods Results— PubMed, Embase, Cochrane Central Register Controlled Trials (CENTRAL) were searched randomized trials, until March 2012, that any Food Drug Administration–approved durable stent polymer (sirolimus-eluting [SES], paclitaxel-eluting [PES], everolimus-eluting...
The efficacy and safety of drug-eluting stents (DES) in patients with ST-segment-elevation myocardial infarction (STEMI) is controversial. Consequently, DES implantation has a class IIa indication the American College Cardiology/American Heart Association European Society Cardiology STEMI guidelines.PUBMED, EMBASE, CENTRAL were searched for randomized clinical trials, until March 2013, comparing any 5 Food Drug Administration-approved durable stent polymer (sirolimus eluting stent,...
Abstract Aims Inter‐atrial shunt device therapy has shown mixed results in clinical trials, with ‘non‐responders’ typically showing features of more advanced heart failure. We aimed to analyse the haemodynamic and response a novel left atrial coronary sinus (LA‐CS) patients higher natriuretic peptide (NP) levels, marker disease severity. Methods An analysis population ( n = 95) from ALT‐FLOW early feasibility study ventricular ejection fraction >40% 1‐year follow up was analysed. The...
Background: Renal disease is associated with poor prognosis despite guideline-directed cardiovascular therapy, and outcomes by sex in this population remain uncertain. Methods Results: Patients (n=5213) who underwent a MitraClip procedure the National Cardiovascular Data Registry Transcatheter Valve Therapy registry were evaluated for primary composite outcome of all-cause mortality, stroke, new requirement dialysis creatinine clearance (CrCl). Centers Medicare Medicaid Services–linked data...
Background The role of CT angiography–derived fractional flow reserve (CT-FFR) in pre–transcatheter aortic valve replacement (TAVR) assessment is uncertain. Purpose To evaluate the predictive value on-site machine learning–based CT-FFR for adverse clinical outcomes candidates TAVR. Materials and Methods This observational retrospective study included patients with severe stenosis referred to TAVR after coronary angiography (CCTA) between September 2014 December 2019. Clinical end points...
Abstract Background Data using real‐world assessments of aortic regurgitation (AR) severity to identify rates Heart Valve Team evaluation and valve replacement (AVR), as well mortality among untreated patients, are lacking. The present study assessed these trends in care outcomes for patients with documented AR. Methods Using a deidentified data set (January 2018–March 2023) representing 1,002,853 >18 years age from 25 US institutions participating the egnite Database (egnite, Inc.)...
BackgroundTraditionally, hostile peripheral access patients undergo TAVR via alternative access. We describe the "transfemoral-first" (TF-1) approach in with access.MethodsClinical and procedural data were obtained for all cases performed from August 2016 to July 2017. Computed tomography was used assess iliofemoral arteries. Patients divided into three femoral groups: routine, hostile, prohibitive. attempted TF routine Hostile defined as: (1) arterial segments diameter <5.0 mm; or (2) <5.5...